Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?
Background: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its k...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-11-01
|
Series: | Revista Portuguesa de Pneumologia (English Edition) |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2173511516300185 |
id |
doaj-21f1e32d9c764975ba6d949a5ecef53b |
---|---|
record_format |
Article |
spelling |
doaj-21f1e32d9c764975ba6d949a5ecef53b2020-11-24T22:12:37ZengElsevierRevista Portuguesa de Pneumologia (English Edition)2173-51152016-11-01226308314Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia?J.M. Pereira0A. Azevedo1C. BasÃlio2C. Sousa-Dias3P. Mergulhão4J.A. Paiva5Emergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, Portugal; Department of Medicine, University of Porto Medical School, Porto, Portugal; Corresponding author.Hospital Epidemiology Centre, Centro Hospitalar São João EPE, Porto, Portugal; Department of Clinical Epidemiology, Predictive Medicine and Public Health, University of Porto Medical School, Portugal; EPIUnit â Institute of Public Health, University of Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, Portugal; Department of Medicine, University of Porto Medical School, Porto, PortugalEmergency and Intensive Care Department, Centro Hospitalar São João EPE, Porto, Portugal; Department of Medicine, University of Porto Medical School, Porto, PortugalBackground: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its kinetics as an early predictor of response in severe CAP (SCAP). Materials and methods: Prospective, single-center, cohort study of 19 SCAP patients admitted to the ICU within 12 h after the first antibiotic dose. Results: At ICU admission median MR-proADM was 3.58 nmol/l (IQR: 2.83â10.00). No significant association was found between its serum levels at admission and severity assessed by SAPS II (Spearman's correlation = 0.24, p = 0.31) or SOFA score (SOFA < 10: <3.45 nmol/l vs. SOFA â¥Â 10: 3.90 nmol/l, p = 0.74). Hospital and one-year mortality were 26% and 32%, respectively. No significant difference in median MR-proADM serum levels was found between survivors and non-survivors and its accuracy to predict hospital mortality was bad (aROC 0.53). After 48 h of antibiotic therapy, MR-proADM decreased in all but 5 patients (median â20%; IQR â56% to +0.1%). Its kinetics measured by the percent change from baseline was a good predictor of clinical response (aROC 0.80). The best discrimination was achieved by classifying patients according to whether MR-proADM decreased or not within 48 h. No decrease in MR-proADM serum levels significantly increased the chances of dying independently of general severity (SAPS II-adjusted OR 174; 95% CI 2â15,422; p = 0.024). Conclusions: In SCAP patients, a decrease in MR-proADM serum levels in the first 48 h after ICU admission was a good predictor of clinical response and better outcome. Keywords: Proadrenomedullin, Biomarkers, Severe community acquired pneumonia, Outcome, Critically ill patientshttp://www.sciencedirect.com/science/article/pii/S2173511516300185 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
J.M. Pereira A. Azevedo C. BasÃlio C. Sousa-Dias P. Mergulhão J.A. Paiva |
spellingShingle |
J.M. Pereira A. Azevedo C. BasÃlio C. Sousa-Dias P. Mergulhão J.A. Paiva Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? Revista Portuguesa de Pneumologia (English Edition) |
author_facet |
J.M. Pereira A. Azevedo C. BasÃlio C. Sousa-Dias P. Mergulhão J.A. Paiva |
author_sort |
J.M. Pereira |
title |
Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? |
title_short |
Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? |
title_full |
Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? |
title_fullStr |
Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? |
title_full_unstemmed |
Mid-regional proadrenomedullin: An early marker of response in critically ill patients with severe community-acquired pneumonia? |
title_sort |
mid-regional proadrenomedullin: an early marker of response in critically ill patients with severe community-acquired pneumonia? |
publisher |
Elsevier |
series |
Revista Portuguesa de Pneumologia (English Edition) |
issn |
2173-5115 |
publishDate |
2016-11-01 |
description |
Background: Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker with potential prognostic utility in patients with community-acquired pneumonia (CAP). Purpose: To evaluate the value of MR-proADM levels at ICU admission for further severity stratification and outcome prediction, and its kinetics as an early predictor of response in severe CAP (SCAP). Materials and methods: Prospective, single-center, cohort study of 19 SCAP patients admitted to the ICU within 12 h after the first antibiotic dose. Results: At ICU admission median MR-proADM was 3.58 nmol/l (IQR: 2.83â10.00). No significant association was found between its serum levels at admission and severity assessed by SAPS II (Spearman's correlation = 0.24, p = 0.31) or SOFA score (SOFA < 10: <3.45 nmol/l vs. SOFA â¥Â 10: 3.90 nmol/l, p = 0.74). Hospital and one-year mortality were 26% and 32%, respectively. No significant difference in median MR-proADM serum levels was found between survivors and non-survivors and its accuracy to predict hospital mortality was bad (aROC 0.53). After 48 h of antibiotic therapy, MR-proADM decreased in all but 5 patients (median â20%; IQR â56% to +0.1%). Its kinetics measured by the percent change from baseline was a good predictor of clinical response (aROC 0.80). The best discrimination was achieved by classifying patients according to whether MR-proADM decreased or not within 48 h. No decrease in MR-proADM serum levels significantly increased the chances of dying independently of general severity (SAPS II-adjusted OR 174; 95% CI 2â15,422; p = 0.024). Conclusions: In SCAP patients, a decrease in MR-proADM serum levels in the first 48 h after ICU admission was a good predictor of clinical response and better outcome. Keywords: Proadrenomedullin, Biomarkers, Severe community acquired pneumonia, Outcome, Critically ill patients |
url |
http://www.sciencedirect.com/science/article/pii/S2173511516300185 |
work_keys_str_mv |
AT jmpereira midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia AT aazevedo midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia AT cbasalio midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia AT csousadias midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia AT pmergulhao midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia AT japaiva midregionalproadrenomedullinanearlymarkerofresponseincriticallyillpatientswithseverecommunityacquiredpneumonia |
_version_ |
1725803081314074624 |